Wegovy Before and After 6 Weeks: What Does Early Weight Loss Actually Look Like?

Why six weeks is a decision point, not a finish line

The question our prescribers hear most weeks goes something like this: "I've been on it six weeks and I've only lost a few kilograms, is it working?" The honest answer is that six weeks is almost always too early to judge Wegovy's full effect. The licensed titration schedule moves from 0.25 mg to 0.5 mg at week five, and the therapeutic maintenance dose of 2.4 mg isn't reached until around week seventeen at the earliest. If you're curious about how long before weight loss on Wegovy becomes noticeable, the answer depends heavily on where you are in the titration, not just how many weeks have passed.

What six weeks can tell you is whether the medicine is being tolerated. Appetite changes (eating less at meals, feeling full faster, fewer cravings in the evening) are the earliest functional signs that semaglutide is doing its job. If those signals are absent and no weight loss at all has occurred, that's worth discussing with your prescriber. A small but real reduction in appetite and a 1–4% body-weight loss is, for most people at this stage, a good indicator that the full titration will produce meaningful results. How long Wegovy takes to work depends heavily on reaching a dose your body responds to therapeutically, which happens later in the schedule.

Photographing yourself or tracking measurements at six weeks is worthwhile, not because major changes are visible, but because the before-and-after comparison you'll use to assess progress is most useful when the "before" is captured properly at the start.

What the STEP 1 trial says about early results

The STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo, published in the New England Journal of Medicine) remains the core evidence base for Wegovy's effectiveness. The headline figure is around 15% average body-weight reduction over the full 68 weeks. Disaggregating what happens in the first six to eight weeks of that data, weight loss is real but comparatively small: early-phase reductions of roughly 2–4% are typical, with losses accelerating substantially from months three to six as the dose increases.

This acceleration matters for anyone comparing six-week before-and-after photos and feeling underwhelmed. The biology of semaglutide's GLP-1 receptor pathway means appetite suppression deepens as the dose rises, the 2.4 mg maintenance dose suppresses hunger considerably more than 0.5 mg does. So the biggest changes in how you eat, and therefore what you lose, come later.

Context also shapes what six-week results look like. Starting weight, diet quality during treatment, and physical activity all influence pace. Someone starting at 110 kg and losing 3% will see a different number than someone starting at 85 kg losing the same percentage, even though both are tracking normally. Browsing Wegovy before and after accounts from real patients can help set realistic expectations, since outcomes vary widely depending on starting weight and lifestyle factors. Wegovy results before and after vary widely in the real world for exactly these reasons.

Side effects at six weeks and what to do about them

Nausea is the most commonly reported side effect at this stage, and for many people it peaks in the first four to eight weeks before settling. The low starting dose of 0.25 mg exists precisely to reduce this, moving too quickly through the titration tends to worsen it. Other GI effects like loose stools, constipation, burping and indigestion are common but usually mild and temporary. Fatigue shows up for some people in the first weeks.

If side effects are tolerable but present, most people find they reduce meaningfully by week eight to ten. If they're severe or not improving, that's a conversation for your prescriber rather than something to push through alone. Staying hydrated matters, GI symptoms increase the risk of dehydration, and dehydration in turn can make nausea worse.

The MHRA's safety guidance for semaglutide asks patients to seek urgent medical attention for severe, persistent abdominal pain, particularly pain radiating to the back, as this can indicate pancreatitis. That's rare, but worth knowing. Any suspected side effect can be reported through the MHRA Yellow Card scheme.

Planning the months ahead after your six-week check-in

At six weeks most people are still deciding whether Wegovy is the right long-term fit. The practical things to assess: appetite is noticeably reduced, weight is moving (even if slowly), and side effects are manageable. If all three are true, continuing through the titration is likely to deliver results that look much more significant in a proper before-and-after comparison at six months.

Wegovy is licensed for weight management alongside a reduced-calorie diet and increased activity, and the lifestyle component is not decoration. People who track protein intake and stay active during titration tend to preserve more lean mass and see better overall results. Eating patterns shift naturally on semaglutide (meals become smaller) so what you choose to eat within that reduced appetite matters more, not less.

If you're thinking about what treatment could look like for you, checking your eligibility takes a few minutes and is reviewed the same day by a GPhC-registered prescriber. It's worth having a look at how Wegovy weight loss before and after develops over longer timeframes before drawing conclusions from the six-week mark. For a broader picture of the available options, the treatment overview covers what is currently licensed and dispensed. And for context on what private treatment involves financially, Wegovy pricing is explained in full.